Delivery Order SPE2DB22D1106-SPE2DB25FELD6
Award Date
4/29/25
Potential Completion Date
4/30/25
Potential Value
$36K
Federal Agency
Defense Logistics Agency
Awardee
Amerisourcebergen Drug Corp
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $6,837.84, is for the supply of 4,567,957,202 units of the pharmaceutical product Dupixent 300 mg/2 ml pen (2 ml). The contract has an ultimate completion date of April 18, 2025. AmerisourceBergen Drug Corp is the prime contractor, and there is no set-aside designation indicated....
This is a $36,916.53 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of the drug Dupixent 300 mg/2 ml pen, with a period of performance through April 2025. This order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, which serves as a primary vehicle for providing pharmaceutical products...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The $56,782.04 contract is for the supply of 4,564,479,370 units of the pharmaceutical product Dupixent 300 mg/2 ml pen 2 ml. The contract has an ultimate completion date of May 3, 2024. AmerisourceBergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC)...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor, for the supply of 4,565,820,356 units of the medication Dupixent 300 mg/2 ml pen. The contract has a firm fixed price of $72,774.35 and a completion date of September 17, 2024. This order is not associated with a set-aside program. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to...
This is a $14,980.56 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of Dupixent 300 mg/2 ml pen, which is a medication used to treat certain medical conditions. The contract has an ultimate completion date of April 8, 2025 and was awarded on April 7, 2025. There is no set-aside designation mentioned for this contract. AmerisourceBergen Drug Corp also holds a...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $36,324.82, is for the supply of Dupixent 300 mg/2 ml pen (2 ml) to support federal agency medical requirements. It is a firm fixed-price contract with an ultimate completion date of April 11, 2025. AmerisourceBergen Drug Corp holds a larger Indefinite Delivery Contract (IDC) with the DLA...
This is a delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $6,609.40, is for the supply of the pharmaceutical product Dupixent 300 mg/2 ml pen with a performance period through November 18, 2024. This order is part of Amerisourcebergen's larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $3,992.85, is for the supply of the medication Dupixent 300 mg/2 ml pen. The order has an ultimate completion date of April 16, 2025. This contract is not associated with a set-aside program and is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen Drug...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $42,219.35, is for the supply of Dupixent 300 mg/2 ml pens. The ultimate completion date for this order is February 28, 2025. This contract is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, valued at...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide 4,563,943,360 units of the pharmaceutical product Dupixent 300 mg/2 ml pen. The contract has a ceiling value of $40,898.97 and a period of performance through March 13, 2024. This delivery order is issued under Amerisourcebergen Drug Corp's existing indefinite delivery contract with DLA, valued at up to...